Showing results (81-90 of 112) with videos related to
Sort By:
Pageof 12
The New England Journal of Medicine|April 9, 2010
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancerJuan Valle, Harpreet Wasan, Daniel H Palmer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaJeffrey Weber, John A Thompson, Omid Hamid, et al.Thrombosis Research|July 29, 2019
The Ottawa score performs poorly in cancer patients with incidental pulmonary embolismFrits I Mulder, Noémie Kraaijpoel, Marcello Di Nisio, et al.Journal of Thrombosis and Haemostasis : JTH|May 31, 2022
Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH SSC subcommittee on hemostasis and malignancyKristen M Sanfilippo, Tzu-Fei Wang, Marc Carrier, et al.Thrombosis and Haemostasis|September 3, 2020
Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study)Nils Picker, Agnes Y Lee, Alexander T Cohen, et al.The Oncologist|April 14, 2018
Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or VomitingHanno Riess, Cihan Ay, Rupert Bauersachs, et al.Journal of Clinical Medicine|October 27, 2022
Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical TrialsKonstantinos G Kyriakoulis, Evangelos Dimakakos, Ioannis G Kyriakoulis, et al.Anticancer Research|July 5, 2022
Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-ArtEvangelos Dimakakos, Georgia Gomatou, Mariella Catalano, et al.Trials|April 15, 2014
A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study protocol for a mixed-methods studyJoanna D Smith, Jessica Baillie, Trevor Baglin, et al.Journal of Thrombosis and Haemostasis : JTH|January 30, 2020
Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)Andrea Marshall, Mark Levine, Catherine Hill, et al.Pageof 12